期刊
BIOMEDICINES
卷 10, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines10071763
关键词
glioblastoma; radioresistance; radiosensitizer; glioma stem cell; tumor hypoxia
资金
- OSU College of Medicine Research Scholarship
This review discusses the treatment modalities for glioblastoma, the mechanisms of radioresistance, and promising radiosensitizers. Small molecules and immunotherapy agents used in conjunction with radiotherapy have been studied in clinical trials. Recent preclinical studies regarding radiosensitizers for glioblastoma are also discussed.
Glioblastoma (GBM) is an aggressive primary brain tumor that is associated with a poor prognosis and quality of life. The standard of care has changed minimally over the past two decades and currently consists of surgery followed by radiotherapy (RT), concomitant and adjuvant temozolomide, and tumor treating fields (TTF). Factors such as tumor hypoxia and the presence of glioma stem cells contribute to the radioresistant nature of GBM. In this review, we discuss the current treatment modalities, mechanisms of radioresistance, and studies that have evaluated promising radiosensitizers. Specifically, we highlight small molecules and immunotherapy agents that have been studied in conjunction with RT in clinical trials. Recent preclinical studies involving GBM radiosensitizers are also discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据